SCHEMBL29508239

SCHEMBL29508239

CC(C)(C)OC(=O)N1CCN(C(C(=O)O)c2cccc(F)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
CYP3A5 P20815 2/20 0.47
GLS O94925 1/20 0.46
GPR119 Q8TDV5 3/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
TP53 P04637 1/20 0.42
GRM5 P41594 1/20 0.41
GRM1 Q13255 1/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MMP13 P45452 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19668491 1.00 CYP3A4 (0.47) CYP3A4CYP3A5GLSGPR119MEN1
SCHEMBL1852622 0.86 GLS (0.57) CYP3A4CYP3A5GLSGPR119MEN1
SCHEMBL5183732 0.85 MEN1 (0.49) CYP3A4CYP3A5GLSGPR119MEN1
SCHEMBL5184046 0.85 ALDH1A1 (0.46) CYP3A4CYP3A5GLSMEN1KMT2A
SCHEMBL4883412 0.82 CYP3A4 (0.52) CYP3A4CYP3A5GLSGPR119MEN1
SCHEMBL13476475 0.81 P2RX3 (0.48) GLSGPR119ATMLMNANPC1
SCHEMBL14128435 0.79 GPR119 (0.50) CYP3A4CYP3A5GLSGPR119MEN1
SCHEMBL19668532 0.79 CFTR (0.46) CYP3A4CYP3A5GLSNPC1ALDH1A1
SCHEMBL19668681 0.79 CYP3A4 (0.59) CYP3A4CYP3A5GLSGPR119
SCHEMBL29363322 0.79 CYP3A4 (0.59) CYP3A4CYP3A5GLSGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119731211-A Cross-linked multispecific antibodies 恩拉扎治疗公司 2025-03-28 CN disclosed
CN-119136842-A Cyclodextrin complexes that specialize in resolution mediators 西蒂斯制药有限责任公司 2024-12-13 CN disclosed
CN-118922209-A Cross-linked antibodies 恩拉扎治疗公司 2024-11-08 CN disclosed
WO-2024229281-A1 ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF CITY OF HOPE (US) 2024-11-07 WO disclosed
EP-4452333-A1 CROSSLINKING ANTIBODIES Enlaza Therapeutics, Inc. (US) 2024-10-30 EP disclosed
CN-111902394-B Compositions and methods relating to salts of specific pro-inflammatory regressive mediators 西蒂斯制药有限责任公司 2024-03-08 CN disclosed
EP-4301767-A1 BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF The Regents of the University of California (US) 2024-01-10 EP disclosed
CN-117098768-A Biologically reactive compounds and methods of use thereof 加利福尼亚大学董事会 2023-11-21 CN disclosed
WO-2023122753-A1 CROSSLINKING ANTIBODIES ENLAZA THERAPEUTICS, INC. (US) 2023-06-29 WO disclosed
EP-4200444-A1 METHODS AND COMPOSITIONS FOR REDUCING NUCLEOTIDE IMPURITIES Singular Genomics Systems, Inc. (US) 2023-06-28 EP disclosed
EP-4117640-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF The Regents of the University of California (US) 2023-01-18 EP disclosed
WO-2022241041-A2 ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF CITY OF HOPE (US) 2022-11-17 WO disclosed
WO-2022236176-A2 FXA PROTEIN FOR TREATING AND/OR PREVENTING COVID-19 CITY OF HOPE (US) 2022-11-10 WO disclosed
CN-109562186-B Compositions and methods relating to salts of specialized proresolving mediators 西蒂斯制药有限责任公司 2022-09-13 CN disclosed
WO-2022187273-A1 BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-09-09 WO disclosed
WO-2022094415-A1 METHODS AND COMPOSITIONS FOR REDUCING NUCLEOTIDE IMPURITIES Singular Genomics Systems, Inc. (US) 2022-05-05 WO disclosed
WO-2022076369-A1 A FACTOR H BINDING PROTEIN B (FHBB) BASED CHIMERIC VACCINE FOR THE PREVENTION AND TREATMENT OF PERIODONTAL DISEASE VIRGINIA COMMONWEALTH UNIVERSITY (US) 2022-04-14 WO disclosed